



## Tecentriq® (atezolizumab) – Expanded indication

- On December 4, 2019, [Roche](#) announced the [FDA approval](#) of [Tecentriq \(atezolizumab\)](#), in combination with [Abraxane® \(paclitaxel protein-bound\)](#) and [carboplatin](#), for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
  - Tecentriq was previously approved for this same indication in combination with [Avastin® \(bevacizumab\)](#), [paclitaxel](#), and carboplatin and as a single-agent for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
- Tecentriq is also approved for the treatment of urothelial carcinoma, locally advanced or metastatic triple-negative breast cancer, and small cell lung cancer.
- The approval of Tecentriq for the expanded indication was based on IMpower130, a randomized, open-label study in patients with stage IV non-squamous NSCLC. Patients received Tecentriq plus chemotherapy (Abraxane and carboplatin) or chemotherapy alone (Abraxane and carboplatin). Major efficacy outcome measures were progression-free survival (PFS) and overall survival (OS) in the subpopulation of patients (N = 681) evaluated for and documented to have no EGFR or ALK genomic tumor aberrations.
  - Median OS was 18.6 months and 13.9 months for Tecentriq plus chemotherapy vs. chemotherapy alone, respectively (hazard ratio [HR] 0.80; 95% CI: 0.64, 0.99; p = 0.0384).
  - Median PFS was 7.2 months and 6.5 months for Tecentriq plus chemotherapy vs. chemotherapy alone, respectively (HR 0.75; 95% CI: 0.63, 0.91; p = 0.0024).
- The recommended dose of Tecentriq (when used in combination with platinum-based chemotherapy) for the treatment of NSCLC is 1200 mg intravenously (IV) every 3 weeks until disease progression or unacceptable toxicity.
  - Refer to the drug labels for the chemotherapy agents administered in combination with Tecentriq for recommended dosing information.
  - Refer to the Tecentriq drug label for dosing for all its other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.